Global outcomes of ST-elevation myocardial infarction: Comparisons of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) registry and trial

American Heart Journal

Volumn 154, Issue 1, 2007, Pages 54-61

  Steinberg, Benjamin A ^a   Moghbeli, Nazanin ^a   Buros, Jacqueline ^a   Ruda, Mikhail ^b   Parkhomenko, Alexander ^c   Raju, B Soma ^d   García Castillo, Armando ^e   Janion, Marianna ^f   Nicolau, José C ^g   Fox, Keith A A ^h   Morrow, David A ^a   Gibson, C Michael ^a   Antman, Elliott M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b INSTITUTE OF CARDIOLOGY   (Poland)

^c Ukranian Strazhesko Institute of Cardiology   (Ukraine)

^d CARE HOSPITAL   (India)

^e Hospital Enfermedades Cardiovasculares y Torax   (Mexico)

^f Swietokrzyskie Centrum Kardiologii Poland   (Poland)

^g UNIVERSITY OF SÃO PAULO   (Brazil)

^h UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ENOXAPARIN; FIBRINOLYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; STREPTOKINASE; THIENO[2,3 B]PYRIDINE DERIVATIVE;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FIBRINOLYTIC THERAPY; HEART MUSCLE REPERFUSION; HOSPITAL PATIENT; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGISTER; RISK ASSESSMENT; ST SEGMENT ELEVATION; TREATMENT OUTCOME;

ENOXAPARIN; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; RANDOMIZED CONTROLLED TRIALS; REGISTRIES; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34250645006     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.03.047     Document Type: Article

References (21)

1. Keeley E.C., Boura J.A., and Grines C.L. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 361 (2003) 13-20
2. Keeley E.C., Boura J.A., and Grines C.L. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. Lancet 367 (2006) 579-588
3. Antman E.M., Morrow D.A., McCabe C.H., et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 354 (2006) 1477-1488
4. Yusuf S., Mehta S.R., Chrolavicius S., et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 295 (2006) 1519-1530
5. Bahit M.C., Cannon C.P., Antman E.M., et al. Direct comparison of characteristics, treatment, and outcomes of patients enrolled versus patients not enrolled in a clinical trial at centers participating in the TIMI 9 trial and TIMI 9 registry. Am Heart J 145 (2003) 109-117
6. Steg P.G., Goldberg R.J., Gore J.M., et al. Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol 90 (2002) 358-363
7. Wiviott S., Morrow D., Giugliano R., et al. Performance of the thrombolysis in myocardial infarction risk index for early acute coronary syndrome in the National Registry of Myocardial Infarction: a simple risk index predicts mortality in both ST and non-ST elevation myocardial infarction. J Am Coll Cardiol 41 Suppl A (2003) 365A-366A
8. Yan A.T., Jong P., Yan R.T., et al. Clinical trial-derived risk model may not generalize to real-world patients with acute coronary syndrome. Am Heart J 148 (2004) 1020-1027
9. Pilote L., Califf R.M., Sapp S., et al. Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. N Engl J Med 333 (1995) 565-572
10. Saleh S.S., Hannan E.L., and Ting L. A multistate comparison of patient characteristics, outcomes, and treatment practices in acute myocardial infarction. Am J Cardiol 96 (2005) 1190-1196
11. Giugliano R.P., Llevadot J., Wilcox R.G., et al. Geographic variation in patient and hospital characteristics, management, and clinical outcomes in ST-elevation myocardial infarction treated with fibrinolysis. Results from InTIME-II. Eur Heart J 22 (2001) 1702-1715
12. Van de Werf F., Topol E.J., Lee K.L., et al. Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. JAMA 273 (1995) 1586-1591
13. Orlandini A., Diaz R., Wojdyla D., et al. Outcomes of patients in clinical trials with ST-segment elevation myocardial infarction among countries with different gross national incomes. Eur Heart J 27 (2006) 527-533
14. Morrow D.A., Antman E.M., Giugliano R.P., et al. A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy. Lancet 358 (2001) 1571-1575
15. Antman E.M., Morrow D.A., McCabe C.H., et al. Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25). Am Heart J 149 (2005) 217-226
16. World Bank Development Indicators Database. In: World Bank; 2004.
17. Norton E.C. Computing interaction effects and standard errors in logit and probit models. Stata J 4 (2004) 103-116
18. Statacorp. Stata Statistical Software: Release 9.2 (2005), College Station, Statacorp (Tex)
19. Gross C.P., Krumholz H.M., Wye G.V., et al. Does random treatment assignment cause harm to research participants?. PLoS Med 3 (2006) e188
20. Alter D.A., Chong A., Austin P.C., et al. Socioeconomic status and mortality after acute myocardial infarction. Ann Intern Med 144 (2006) 82-93
21. Banks J., Marmot M., Oldfield Z., et al. Disease and disadvantage in the United States and in England. JAMA 295 (2006) 2037-2045